[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-preconditioning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-preconditioning":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100579503","early-phase-1-therapeutic-strategies-to-reduce-endothelial-ischemia-reperfusion-injury-100579503",false,"NCT06825143","Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury","Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury with Metabolic Syndrome: a Combination Approach with Lactate Administration and Ischemic Preconditioning","Inclusion Criteria:\n\n* Sedentary men and women between the ages of 18-65 years of all races and ethnicity\n* Diet and weight stable for the past 3 months\n* Non-smoking and not using tobacco or electronic cigarettes\n\nExclusion Criteria:\n\n* Use of medications known to affect cardiovascular function\n* Hyperlactemia\n* Type A lactic acidosis\n* Type B lactic acidosis\n* Extracellular hyperhydration or hypervolemia\n* Hyperkaliemia\n* Hypercalcemia\n* Metabolic alkalosis\n* Metabolic acidosis\n* McArdle's Disease\n* Diabetes Type 1 and 2\n* Taking oral contraceptives or hormone replacement therapy\n* Body mass index greater than or equal to 35\n* Smoking or using smokeless tobacco and electronic cigarettes\n* Cardiovascular, cerebrovascular, liver, respiratory, and renal disease\n* Atrial fibrillation or other sustained supraventricular\u002Fventricular arrhythmia\n* Familial hypercholesterolemia\n* Rheumatoid arthritis\n* Sleep apnea\n* Currently pregnant, recent pregnancy, or breast-feeding\n* Autonomic nervous system dysfunction\n* Raynaud's disease\n* Active malignancy excluding basal cell carcinoma of the skin\n* Three or more days of at least 30 minutes of aerobic exercise in the past 3 months\n* Inability to provide consent",true,"ALL","18 Years","65 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The objective of this clinical trial is to better understand how lactate, a naturally occurring energy substance, can be used to lessen damage to the vascular system in adults with a high cardiovascular disease risk.\n\nThe main questions it aims to answer are:\n\n1. Does giving lactate intravenously reduce injury to the vascular system?\n2. Does giving lactate intravenously together with blood flow occlusion - known as ischemic preconditioning, reduce vascular injury better than blood flow occlusion by itself?\n3. How does lactate help the vascular system?\n\nResearchers will compare lactate to a placebo (a look-alike substance that contains no lactate) to see if lactate works to lessen vascular injury.\n\nResearchers will also compare lactate to blood flow occlusion to see which one is better at preventing vascular injury.\n\nResearchers will also compare lactate and blood flow occlusion together to see if combining them works better than either one alone.\n\nIn one visit to the laboratory, participants will:\n\nObtain a measurement of vascular health in an arm Be given liquid lactate, a liquid placebo, and\u002For arm blood flow occlusion Obtain a second measurement of vascular health in an arm.",[28,29,30,31,32],"Metabolic Syndrome","Vascular Injury","Ischemic Preconditioning","Endothelial Function (reactive Hyperemia)","Endothelial Dysfunction",[34,35,36,37],"endothelial ischemia\u002Freperfusion injury","remote ischemic preconditioning","lactate","metabolic syndrome","NOT_YET_RECRUITING","2025-02-07",{"date":41,"type":42},"2025-02-13","ACTUAL",{"date":44,"type":22},"2026-10-01",{"date":46,"type":22},"2030-06-30",{"name":48,"class":49},"Gary Van Guilder","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":50},"100470978","effect-of-coq10-on-the-endocrine-function-of-skeletal-muscle-100470978","NCT05412888","Effect of CoQ10 on the Endocrine Function of Skeletal Muscle","The Effect of Ischemic Preconditioning and Physical Exercise on the Endocrine Function of Skeletal Muscle - the Effect of CoQ10 Supplementation. In Vivo and in Vitro Studies.","Inclusion Criteria: - gender (males only),\n\n* not taking medication during the study,\n* good health (no concomitant injuries),\n* negative history of cardiovascular disorders, autonomic nervous system, mental disorders, cerebrospinal injuries and other diseases that may directly affect the results obtained.\n\nExclusion Criteria:\n\nLack of consent to participate in the research project or negative result of medical examinations.","MALE","21 Years","29 Years",{"count":62,"type":22},100,[64],"NA","Recent studies have also shown that repeated episodes of ischemia, followed by reperfusion (IPC), can contribute to the development of adaptive changes not only in the area of the heart muscle, but also in the structure of the skeletal muscles.\n\nIn the project, several research questions will be evaluated e.g. what is the relationship between oxidative stress parameters, uric acid concentration and nitric oxide degradation products in groups of people undergoing two-week training in ischemic training, or what is the relationship between the expression of genes associated with muscle cell growth (e.g. myostatin gene) and the effect of ischemia preconditioning training etc.",[30,67,68],"Coenzyme Q Deficiency","Exercise Training",[70,71,72,73],"skeletal muscle","myokines","ischemia","inflammation","2023-01-02",{"date":76,"type":42},"2023-01-04",{"date":78,"type":22},"2023-03-01",{"date":80,"type":22},"2026-09-30",{"name":82,"class":49},"Medical University of Gdansk",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":50},"100489468","remote-ischemic-conditioning-combined-with-endovascular-stenting-for-symptomatic-intracranial-atherosclerotic-stenosis-100489468","NCT05653505","Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis","Safety and Efficacy of Remote Ischemic Conditioning Combined With Endovascular Stenting in Patients With Symptomatic Intracranial Atherosclerotic Stenosis","Inclusion Criteria:\n\n1. Patient admitted from Jan. 1st 2023 to Jan. 1st 2025;\n2. Age ≥ 18;\n3. Intracranial atherosclerosis stenosis measured as ≥70% by digital subtraction angiography or by other noninvasive methods, such as transcranial doppler, computed tomography angiography, or magnetic resonance angiography;\n4. A history of stroke\u002Ftransient ischemic attack attributed to ICAS;\n5. Verbal and written informed consent is provided at the time of admission by patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n1. Stenosis of other causes;\n2. Prior ipsilateral stroke with residual deficits;\n3. Uncontrolled hypertension (defined as systolic blood pressure ≥200 mm Hg despite medications at enrollment);\n4. Peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion).",{"count":91,"type":22},160,"12 Months","OBSERVATIONAL","The purpose of this registry is to evaluate the safety and efficacy of RIC for patients with symptomatic intracranial atherosclerotic stenosis (sICAS) undergoing endovascular therapy.",[96,30,97],"Intracranial Arteriosclerosis","Endovascular Procedures",[99,100,101],"Remote Ischemic Conditioning","Endovascular Stenting","Symptomatic Intracranial Atherosclerotic Stenosis","2022-12-15",{"date":104,"type":42},"2022-12-16",{"date":106,"type":22},"2023-01-01",{"date":108,"type":22},"2026-07-01",{"name":110,"class":49},"Tianjin Huanhu Hospital"]